Another Sea Change in Melanoma: Immune Combo Triumphs
The results likely represent yet another sea change in the treatment of this disease because, to date, single-agent immunotherapy with ipilimumab (Yervoy, Bristol-Myers Squibb) has been the gold standard in the first-line treatment of non-BRAF-mutated disease.
This study shows that first-line nivolumab (Opdivo, Bristol-Myers Squibb), either in combination with ipilimumab or used alone, produced a longer progression-free survival than ipilimumab alone.
Patients were free of disease for twice as long with nivolumab alone as with ipilimumab alone, and nearly four times as long as with the combination.
But the two drugs together are much more toxic than either single agent, and the combination would be very expensive, cautioned study observers. Together, ipilumumab and nivolumab cost nearly $300,000….remaining article with much statistical data and such http://www.medscape.com/viewarticle/845655?src=wnl_edit_cfna#vp_1